Search

Displaying results 4731 - 4740 of 6198 in total
  1. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  2. Drug

    Gamithromycin

    go.drugbank.com/drugs/DB11416
    ExperimentalVet approved

    Gamithromycin is an antibiotic used in cattle.

  3. Drug

    R3R01

    go.drugbank.com/drugs/DB18078
    Investigational

    R3R01 is an investigational lipid-modifying drug.

  4. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological

  5. Drug

    Octyl triazone

    go.drugbank.com/drugs/DB15469
    Investigational

    Mixtures: Kiehls Ultra Light Daily UV Defense Aqua Gel SPF 50 Anti-Pollution
  6. Drug

    S-23

    go.drugbank.com/drugs/DB07419
    Experimental

    An androgen receptor modulator.

  7. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.

  8. Drug

    Senazodan

    go.drugbank.com/drugs/DB19879
    Experimental

    The usage of the INN stem '-dan' in the name indicates that Senazodan is a cardiac stimulant, pimobendan derivative. Senazodan has a monoisotopic molecular weight of 266.12 Da.

  9. Drug

    Adibendan

    go.drugbank.com/drugs/DB20623
    Experimental

    The usage of the INN stem '-dan' in the name indicates that Adibendan is a cardiac stimulant, pimobendan derivative. Adibendan has a monoisotopic molecular weight of 278.12 Da.

  10. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]